• Explore /
  • Poster
  • / Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.

Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.

Abstract Video & Slides Poster

Authors

null

Christos Kyriakopoulos

University of Wisconsin-Madison Carbone Cancer Center, Verona, WI

Christos Kyriakopoulos , Gurkamal S. Chatta , Andrew Leonard Laccetti , Nicholas Iannotti , Alexandra Sokolova , Sebastien J. Hotte , Ronald F. Tutrone , Mark Christopher Markowski , Luke T. Nordquist , Roberto Pili , Fred Saad , Jingsong Zhang , Karen Villaluna , Brett Younginger , Ronan Le Moigne , Alessandra Cesano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05075577

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 141)

DOI

10.1200/JCO.2024.42.4_suppl.141

Abstract #

141

Poster Bd #

F12

Abstract Disclosures

Similar Posters

First Author: Andrew Leonard Laccetti

First Author: Matthew Raymond Smith

First Author: Daniel Petrylak

First Author: Dana E. Rathkopf